| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H31NO2 |
| Molecular Weight | 353.4977 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H](OC(C)=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=XBMIVRRWGCYBTQ-XMSQKQJNSA-N
InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m1/s1
| Molecular Formula | C23H31NO2 |
| Molecular Weight | 353.4977 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Alphacetylmethadol (INN), aka α-acetylmethadol (AAM), is a synthetic opioid analgesic. Its levorotary enantiomer, levacetylmethadol, is an FDA-approved treatment for opioid addiction. Alphacetylmethadol is very similar in structure to methadone, a widely-prescribed treatment for opioid addiction. In the United States, it is a Schedule I controlled substance under the Controlled Substances Act with an ACSCN of 9603 and a 2013 annual manufacturing quota of 2 grams. Studies in rats indicate that alphacetylmethadol also evokes the heroin-like discriminative stimulus effects.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
